Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells in Patients With Metastatic Mesothelin-Expressing Breast Cancer
Conditions
Interventions
Cyclophosphamide
Mesothelin-targeted T cells
+1 more
Locations
7
United States
Memorial Sloan Kettering Cancer Center (Consent and follow-up only)
Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Consent and follow-up only)
Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Consent and follow-up only)
Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center at Commack (Consent and follow-up only)
Commack, New York, United States
Memorial Sloan Kettering Westchester (Consent and follow-up only)
East White Plains, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
June 1, 2016
Primary Completion Date
June 1, 2026
Completion Date
June 1, 2026
Last Updated
July 17, 2025
NCT04541381
NCT05468034
NCT03137095
NCT07547774
NCT04852887
NCT06393374
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions